Logo

TEM

Tempus AI, Inc.

TEM

Tempus AI, Inc. • NASDAQ
$78.16 ▲ 1.23% (+0.95)
Market Cap $13.40 B
52w High $104.32
52w Low $31.36
Dividend Yield 0%
P/E -269.52
Volume 1.75M
Outstanding Shares 171.46M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $334.206M ▲ $265.85M ▲ $-79.982M ▼ -23.932% ▼ $-0.457 ▼ $-37.276M ▼
Q2-2025 $314.635M ▲ $256.813M ▲ $-42.843M ▲ -13.617% ▲ $-0.247 ▲ $9.08M ▲
Q1-2025 $255.737M ▲ $223.892M ▲ $-68.037M ▼ -26.604% ▼ $-0.399 ▼ $-73.978M ▼
Q4-2024 $200.68M ▲ $172.764M ▲ $-13.014M ▲ -6.485% ▲ $-0.08 ▲ $12.46M ▲
Q3-2024 $180.929M $159.455M $-75.84M -41.917% $-0.458 $-50.909M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $759.638M ▲ $2.281B ▲ $1.774B ▲ $507.824M ▲
Q2-2025 $291.306M ▲ $1.625B ▲ $1.316B ▲ $309.562M ▼
Q1-2025 $218.786M ▼ $1.543B ▲ $1.217B ▲ $326.194M ▲
Q4-2024 $448.263M ▼ $926.116M ▼ $869.777M ▼ $56.339M ▲
Q3-2024 $466.323M $971.728M $918M $53.728M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-79.982M ▼ $-119.842M ▼ $-2.309M ▲ $594.69M ▲ $472.498M ▲ $-126.548M ▼
Q2-2025 $-42.843M ▲ $44.164M ▲ $-9.511M ▲ $0 ▼ $34.725M ▲ $34.653M ▲
Q1-2025 $-68.037M ▼ $-105.624M ▼ $-375.818M ▼ $293.042M ▲ $-188.509M ▼ $-108.996M ▼
Q4-2024 $-13.014M ▲ $-39.251M ▼ $-7.962M ▲ $-179K ▲ $-47.043M ▲ $-47.213M ▼
Q3-2024 $-75.84M $48.664M $-131.412M $-8.123M $-90.794M $48.621M

Five-Year Company Overview

Income Statement

Income Statement Tempus AI shows a young, fast-growing business with revenue rising steadily each year, and gross profitability improving as the platform scales. At the same time, operating costs are still far ahead of sales, leading to sizable and persistent losses. Those losses have recently widened, suggesting the company is still in heavy investment mode rather than focusing on near-term profitability. The overall picture is a growth-first strategy that relies on future scale and efficiency gains to eventually narrow losses.

Balance Sheet

Balance Sheet The balance sheet reflects a company that has been funded largely by outside capital, with debt playing a meaningful role and equity only recently turning positive, likely thanks to new financing tied to its market debut. Cash levels are material relative to the size of the business, which provides some operating runway, but not yet the comfort of a self-funding model. Debt obligations add financial risk if the path to profitability takes longer than expected or funding conditions tighten. Overall, the balance sheet is adequate for a high-growth tech-healthcare company but not yet conservative.

Cash Flow

Cash Flow Tempus AI continues to consume cash rather than generate it, with operating cash outflows consistently negative over several years. Importantly, the cash burn has not exploded as the company has grown, indicating some emerging discipline and operating leverage, but it remains a clear drain. Free cash flow is also negative, and capital spending is relatively modest, implying that most cash use is tied to people, data, and technology rather than physical assets. The business still depends on access to external capital markets to fund its growth plans.

Competitive Edge

Competitive Edge Competitively, Tempus sits in a strong niche at the intersection of AI, genomics, and clinical data, supported by one of the more extensive multimodal healthcare datasets in the market. Deep integration into physician workflows, relationships with major pharmaceutical companies, and a vertically integrated data pipeline create real switching costs and network effects. Patents and proprietary algorithms further reinforce this position. However, the space is crowded and strategic, attracting large tech, diagnostics, and data players, so Tempus’s advantage is meaningful but not unassailable and must be actively defended through continued execution.

Innovation and R&D

Innovation and R&D Innovation is the core of Tempus’s story: from genomic profiling and AI-based diagnostics to trial matching, clinical decision support tools, and patient-facing apps. The company is expanding beyond oncology into other therapeutic areas and is pushing into AI-driven drug discovery and more advanced generative AI applications. Regulatory approvals for its tests and platforms are key value drivers, as they can unlock broader clinical adoption and reimbursement. The strategy also includes targeted acquisitions to deepen capabilities and data, which accelerates innovation but adds integration and execution risk.

Summary

Tempus AI is an early-stage, data-rich healthcare technology company trading near the frontier of AI in medicine, with strong top-line growth but persistent, sizable losses and continued cash burn. Its value proposition rests on a rare combination of large-scale clinical and molecular data, sophisticated AI tools, and tight integration into clinical and pharma workflows. Financially, the company is still very much in the build-out phase, leaning on capital markets and carrying a meaningful debt load, with profitability likely a medium-term, not near-term, goal. The key variables to watch are revenue growth versus cost growth, progress toward regulatory approvals and reimbursement, the depth of customer adoption, and the company’s ability to maintain its data and AI edge in a highly competitive landscape without overstretching its balance sheet.

NEWS

November 18, 2025 · 8:30 AM UTC

Tempus to Participate in the Piper Sandler 37th Annual Healthcare Conference

Read more

November 14, 2025 · 8:30 AM UTC

Tempus and IFLI Announce Study to Advance Follicular Lymphoma Research

Read more

November 5, 2025 · 8:30 AM UTC

Tempus Announces Six Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer Annual Meeting 2025

Read more

November 4, 2025 · 4:01 PM UTC

Tempus Reports Third Quarter 2025 Results

Read more

October 28, 2025 · 8:30 AM UTC

Tempus to Participate in the Stifel 2025 Healthcare Conference

Read more